Biomerica Announces Second Quarter Financial Results; Sales Up 6.4% for the Quarter
January 15, 2020 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,596,408 for the three months ended November 30, 2019, compared to $1,500,791 for the...
Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial
January 07, 2020 08:19 ET
|
Biomerica, Inc.
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities)InFoods® Diagnostic...
Biomerica Announces Fiscal Year End 2019 Financial Results
August 30, 2019 08:30 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682...
Irritable Bowel Syndrome Treatment Market Size Worth Around US$ 3.4 Bn by 2026
July 16, 2019 14:00 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, Recently Published Report titled “Irritable Bowel Syndrome Treatment Market Size, Share, Trends, Growth and Forecast 2019-2026”. LOS ANGELES, July 16, 2019 (GLOBE...
Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
May 29, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
May 13, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
April 08, 2019 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Why IBS Affects Women Differently: A Capital Digestive Care GI Explains
February 26, 2019 08:24 ET
|
Capital Digestive Care
Silver Spring, MD, Feb. 26, 2019 (GLOBE NEWSWIRE) -- By Leigh Lurie, MD IBS (irritable bowel syndrome) affects about 10% of the global population, making it the most common GI disorder in the...
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
September 12, 2018 07:00 ET
|
RedHill Biopharma Ltd.
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders ...
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
September 06, 2018 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the...